Investor Bill Ackman is in court today over insider trading allegations in the deal between Allergan and Valeant Pharmaceuticals, reports CNBC's Kate Kelly.» Read More
Testimony from Federal Reserve Chair Janet Yellen and Ukraine are what traders say could most affect markets in the week ahead.
Cramer says there will be plenty of opportunities to make money in the week ahead. But you'll have to stay alert and move fast.
Mario Gabelli said the partnership of activist investor Bill Ackman and Valeant Pharmaceuticals to try to buy Allergan was unfair.
Happy Friday, which is, of course Jobs Friday. Seems like we just had one of these a month ago.
Billionaire investor Mario Gabelli told CNBC on Friday the unique arrangement to try to buy Botox-maker Allergan is unfair.
Some market watchers consider Ackman's gambit to be the latest flavor of legal insider trading—and an unappetizing one as well.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Headlines after the bell Wednesday: Allergan, MetLife, Yelp
Bill Ackman and Carl Icahn, whose epic battle on CNBC stunned Wall Street, exchanged pleasantries last week and decided to forgive each other.
Argus Research's John Eade weighs in on growing M&A in the pharma space.
What a week on "Squawk Box"! Bill Ackman teams up with Valeant to buy Botox-maker Allergan. Novartis' buying and selling and lil' Squawkers running the show.
Allergan may be more effective in its defense against a hostile takeover bid by Valeant Pharmaceuticals if it makes a purchase of its own, an analyst says.
This is an unofficial transcript of Warren Buffett's April 23, 2014 live appearance on CNBC's "Closing Bell"
Warren Buffett discusses activist investing and shares his thoughts on David Winters and Bill Ackman.
CNBC's Kate Kelly reports Bill Ackman did the bulk of his buying of Allergan through the off-exchange options market.
Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.
Maybe it was the martini that helped Carl Icahn publicly support longtime nemesis Bill Ackman, but he still calls Marty Lipton "dead wrong."
Happy Wednesday and welcome to the Morning Six-Pack, where we're always trying to beat analyst estimates and surprise to the upside.
Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.